Decoding 10 Analyst Evaluations For Ultragenyx Pharmaceutical
Portfolio Pulse from Benzinga Insights
In the past three months, 10 analysts have rated Ultragenyx Pharmaceutical (NASDAQ:RARE), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has increased by 3% to $89.2. Analysts have adjusted their ratings and price targets, reflecting a positive outlook on the company's market position and financial performance.
October 21, 2024 | 8:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Ultragenyx Pharmaceutical has received a mix of bullish and somewhat bullish ratings from analysts, with a 3% increase in the average 12-month price target to $89.2. This reflects a positive sentiment towards the company's market position and financial performance.
The increase in the average price target and the predominance of bullish ratings suggest a positive short-term outlook for Ultragenyx Pharmaceutical. Analysts' actions, such as raising price targets and maintaining positive ratings, indicate confidence in the company's market position and financial performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100